Dermatitis News

Kyowa Kirin reported positive phase 2 study results for KHK4083 in treating atopic dermatitis compared with placebo, according to a press release.

A new drug application under priority review for ruxolitinib cream for the treatment of atopic dermatitis has been accepted by the FDA, Incyte announced in a press release.

Individuals with atopic dermatitis carried an elevated risk for asthma compared with those who did not have AD, according to a study.

Patients with skin of color have unique challenges when it comes to treating psoriasis.

Lebrikizumab had “generally consistent” results in improving atopic dermatitis across different races, according to results of a phase 2b study presented at Maui Derm for Dermatologists.

Patients with moderate to severe atopic dermatitis experienced improvement in symptoms when treated with tralokinumab plus topical corticosteroids, according to a study presented at the Winter Clinical Dermatology Conference.

Arcutis Biotherapeutics will begin a phase 3 trial of roflumilast foam for the treatment of seborrheic dermatitis, the company announced in a press release.

Arcutis Biotherapeutics has begun two phase 3 trials of topical roflumilast cream for the treatment of atopic dermatitis.

A sensitive formula baby wipe brand with fewer ingredients had fewer days of irritant diaper dermatitis when compared with formulas with more ingredients, according to a study published in Pediatrics and Neonatology.

Proper hand hygiene is essential to reduce COVID-19 transmission and preserve skin barrier integrity, according to a review published in Journal of the American Academy of Dermatology.